Packaged-Food Stocks Fall Over 50% as Flawed GLP-1 Data Faces Scrutiny

(P1) Packaged-food stocks, including giants like General Mills and Conagra, have seen their valuations fall by more than 50% from recent peaks as Wall Street bets that GLP-1 weight-loss drugs will permanently alter consumer spending. However, a detailed analysis published April 6, 2026, suggests this market reaction is based on a fundamental misreading of consumer data.

(P2) "The leap from clinical trials to claims that these drugs are transforming how America shops and eats rests on evidence so thin that any first-year economics student should be skeptical," Roland Fryer, a Harvard economics professor and author of the analysis, wrote in the Wall Street Journal. Fryer argues that the observed behavioral shifts reflect the habits of the drugs' wealthy, health-motivated early adopters, not the effect of the drugs themselves.

(P3) The market's anxiety has been fueled by reports like a 2024 KPMG analysis estimating GLP-1 users consumed 21% fewer calories and a Cornell University study finding users cut grocery spending by 5.3%. These data points contributed to a selloff where the five largest pure-play packaged-food companies fell roughly 18% while the S&P 500 gained 24% over the same period.

(P4) At stake is a multibillion-dollar pivot by the food industry toward "GLP-1-friendly" products. The core of the debate is whether the drugs' pharmacological effect—appetite suppression—will be accompanied by a widespread shift to healthier eating as adoption broadens. The answer will become clearer as Medicare and Medicaid coverage expands, testing whether the "healthy-eating signal was a product of self-selection all along."

The Lululemon Analogy

The current narrative conflates the user with the product. When Lululemon first emerged, its customers were already athletic and health-conscious. A survey comparing them to non-buyers would have shown dramatic differences in diet and exercise, but it would be wrong to conclude that yoga pants caused the behavior. Similarly, GLP-1 users currently skew heavily toward affluent households, with those earning over $100,000 annually being more than twice as likely to use the drugs. Their "kale-buying, snack-aisle-skipping behavior" likely reflects pre-existing inclinations.

As the drugs become accessible to a broader population, this self-selection bias is expected to diminish. If later adopters on Ozempic simply eat half a Big Mac instead of switching to a salad, it will confirm that the observed healthy-eating trend was a feature of the initial user base, not a universal effect of the drug.

Pharmacology vs. Preference

GLP-1 drugs are unambiguously effective at suppressing appetite and reducing "food noise"—intrusive cravings for high-calorie foods. Clinical trials for semaglutide (Ozempic) and tirzepatide (Zepbound) showed average body-weight reductions of 14.9% and up to 20.9%, respectively. However, none of the landmark trials measured changes in dietary composition or food choice in a real-world setting.

The critical distinction is between "buying less" and "buying different." The reduction in total calories is a pharmacological reality that has justifiably repriced food stocks. But the massive industry investment in healthier product lines is a bet on a behavioral shift that remains unproven in the general population.

The Discontinuation Dilemma

Compounding the uncertainty is the high discontinuation rate. Real-world data suggests roughly half of patients prescribed GLP-1 drugs for weight loss stop taking them within 12 months. This challenges the long-term thesis for sustained healthcare savings and productivity gains, which is built on decades of continuous use.

A 2026 study in BMJ Medicine highlighted that interrupting the medication can increase the risk of heart attack, stroke, and death. A world where users cycle on and off the drugs is one where health benefits are intermittent and costs are recurring, potentially making the long-run dividend a fraction of what optimistic models project. For the food industry, it means the "new" GLP-1 consumer may not be a stable, long-term market segment.

This article is for informational purposes only and does not constitute investment advice.